https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4
Skip to content 
Merck & Co. Inc. (NYSE: MRK) on Tuesday reported lower sales and adjusted earnings for the second quarter of 2025. The company also announced the acquisition of Verona Pharma plc. Second-quarter sales were $15.8 billion, compared to $16.1 billion in the prior year quarter. Pharmaceutical sales declined by 2% while Animal Health sales grew by 11%. The company reported … Read more
Merck & Co. signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Tuesday, April 8, 2025. Michael Nagle | Bloomberg | Getty Images Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches … Read more
Merck & Co. Inc. (NYSE: MRK) Thursday reported an increase in adjusted earnings for the first quarter of 2025, while the pharma company’s sales remained broadly unchanged. First-quarter sales were $15.5 billion, compared to $15.8 billion in the prior year quarter. Pharmaceutical sales declined by 3% while Animal Health sales grew by 5%. The company reported … Read more
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the fourth quarter of 2024, aided by a 7% increase in sales. Fourth-quarter worldwide sales increased 7% year-over-year to $15.6 billion, with Pharmaceutical and Animal Health revenues growing 7% and 9% respectively. The company reported a net profit of … Read more
https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4